Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

NIH seeks licensees for michellamine antiviral agents

Dec. 18, 1998

Review of AIDSVAX studies past and present

Dec. 15, 1998

Highly potent anti-HIV betulin derivative acts at a late stage in the viral life cycle

Dec. 14, 1998

Virological and pharmacokinetic profile presented for structurally novel NNRTIs from DuPont

Dec. 14, 1998

Noninfectious HIV particles as immunogens for treating or preventing HIV infection/AIDS

Dec. 11, 1998

Combination tablet that eases pill burden in HIV therapy now available in Canada

Dec. 10, 1998

Orally bioavailable anti-HIV peptides described in patent literature by Japan Energy

Dec. 10, 1998

HHS recommends first PI-sparing AIDS treatment regimen

Dec. 8, 1998

Canadian approval obtained for Serostim

Dec. 4, 1998

New HIV protease inhibitors in development at Monsanto

Dec. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...